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The unusually fast crystallization of the organic compound nifedipine has been investigated in detail using
different solutions as precursors for the formation of the initial glassy nifedipine films. Starting from these
amorphous films the crystallization process was investigated by time-resolved light microscopy at different
temperatures around Tg of nifedipine. In all studied cases (acetone, acetonitrile, ethyl acetate,
dichloromethane, tetrahydrofuran) the measured mean crystallization rates are, on average, 10 000
times higher than rates reported in previous studies. Such high rates cannot be explained by a classical
diffusional crystal growth mechanism of nifedipine. Instead, nifedipine shows a strong propensity for
diffusionless growth. Solvent assisted or solvent induced preordering of the glassy modification is
suggested to be the most probable driving force behind these fast crystallization processes. The nifedipine
crystallization rates can be controlled not only by specific solvent–molecule interactions but also by
temperature. Below 40 uC, the temperature dependence of the rates is generally small. Above 40 uC, a
slowing down of the crystallization rates with increasing temperatures indicates a kinetic competition
between different polymorphs. The molecular dynamics of nifedipine molecules in the amorphous phase
as well as the relaxation times are studied by dielectric measurements. The dielectric data corroborate the
inherently strong propensity of nifedipine to crystallize diffusionlessly under all conditions.
Introduction
Crystallization is one of the key processes in different areas of
science covering inorganic and organic materials. Especially
organic compounds are known for their polymorphism. This
phenomenon characterizes the propensity of a compound to
crystallize in more than one structure.1 Polymorphism directly
affects solid-state properties of the materials, i.e. stability,
dissolution rate of a compound and is therefore of great
importance for the pharmaceutical and fine chemical indus-
tries.2,3 The selective crystallization of a certain polymorph
and its subsequent stabilization remains a challenging task,
since the various thermodynamic and kinetic factors affecting
the crystallization processes are difficult to control. In most
cases the rate determination of the crystallization is still an
experimental challenge.1 Recently, two new phenomena in the
field of organic (molecular) systems crystallizing from the
melts have been described. These two phenomena i) diffusion-
less and ii) surface-enhanced crystallization lead to signifi-
cantly higher crystallization rates than in processes driven only
by bulk diffusion.2,3
Among the compounds studied in this context, nifedipine
(4-(2-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihy-
dropyridine, see Fig. 1) is known for its polymorphism and
high crystallization rates.2–8 Nifedipine is a widely used
antihypertensive and vasodilating drug of the dihydropyridine
type.9 Nifedipine is perfectly suited for crystallization growth
rate studies and has been intensively investigated using
dielectric spectroscopy among other methods.10–19 Recently,
we reported extremely high crystallization rates of nifedipine,
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Fig. 1 Structure of nifedipine (4-(2-nitrophenyl)-2,6-dimethyl-3,5-dicarbo-
methoxy-1,4-dihydropyridine).
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starting from an amorphous film produced via evaporation of
an acetone solution. The crystallization process was studied by
time-resolved Raman micro-spectroscopy. The mean crystal-
lization rate of the initially crystallizing metastable b-form was
found to be four orders of magnitude higher as compared to
those of previous studies. The subsequent crystal conversion
of the b-form to the most stable a-form is again extremely
fast.8 Expanding systematically the acetone pilot study to
different solvents ranging from very polar to non-polar, is the
prime purpose of this study.
Experimental section
Materials
Nifedipine (¢98%, CAS 21829-25-4) was purchased from
Sigma Aldrich and used without further purification. On the
basis of the X-ray diffraction pattern (Bruker AXS, D8, Cu Ka
radiation) and Raman spectra, the material was identified as
the pure thermodynamically stable polymorph a-nifedipine
(P21/c, a = 10.923(5) Å, b = 10.326(6) Å, c = 14.814(7) Å, b =
92.70(6)u, V = 1669.03(494) Å3).20
Acetone (¢99.5%) was purchased from Th. Geyer GmbH &
Co. KG (Renningen, Germany), acetonitrile (¢99.8%) from J.
T. Baker (Deventer, Netherlands), dichloromethane (¢99.5%)
from Carl Roth GmbH + Co. KG (Karlsruhe, Germany),
chloroform (¢99.8%) from Merck KGaA (Darmstadt,
Germany), ethyl acetate (¢99.5%) and tetrahydrofuran
(¢99.9%) from Fluka Chemie GmbH (Buchs, Switzerland).
Sample preparation
Nifedipine solutions were prepared in different solvents:
acetone (182 mM), acetonitrile (72 mM), chloroform (202
mM), dichloromethane (182 mM), ethyl acetate (72 mM), and
tetrahydrofuran (200 mM). The concentration was chosen
significantly below the saturation level in order to avoid the
presence of any crystalline material in the starting solution.
Since nifedipine is slightly light sensitive, especially in
solution, any exposure to light was avoided as far as possible.
The solutions were prepared at ambient conditions and stored
in amber glass vials. In a typical experiment, 20 mL of a freshly
prepared solution of nifedipine were pipetted on a glass slide
(1 mm, Menzel, Braunschweig, Germany) and left for drying in
the dark for typically 1 min. After the solvent evaporated
completely, a thin glassy film of g-nifedipine remained on the
surface. The thickness of the film varies with the solvent.
Usually the films possess thicknesses between 50 and 70 mm.
The surface area is around 1 cm2. Randomly distributed over
the amorphous film, nifedipine started to crystallize statisti-
cally within a few minutes. The crystallization process was
then monitored in situ by light microscopy and Raman
spectroscopy till no more changes proceeded.
Raman spectroscopy
Raman spectroscopy was used for the characterization and the
unambiguous identification of the polymorphs occurring in
the thin nifedipine film.21 The Raman measurements were
performed with a Raman microspectroscopic setup (LabRam,
Horiba–Jobin–Yvon, Bensheim, Germany) equipped with a
BX41 microscope (Olympus, Hamburg, Germany) and a
nitrogen-cooled CCD detector (256 6 1024 pixels). A HeNe-
laser emitting at 633 nm was used for excitation. To reject the
Rayleigh scattered light a filter was used. The spectra were
recorded with an irradiance of 1.6 6 104 W cm22 on the
sample and an acquisition time of typically 5 s and 5
accumulations for the ex situ spectra. All in situ spectra were
recorded with an acquisition time averaging 36 2 s or 56 5 s
adjusted to the crystal growth rate (see Fig. S1–S6, ESI3).
Hot stage microscopy and determination of mean crystal
growth rates
The crystallization of the thin amorphous nifedipine films was
investigated in detail using light microscopy (Leica MZ 12.5,
Leica Microsystems GmbH, Wetzlar, Germany, equipped with
a hot stage and a 2048 6 1536 pixel camera). In each
experiment, a thin film of nifedipine was prepared on a glass
slide as described above. After the crystallization started, the
propagation of one crystallization front was monitored. For
each sample the growth rates of the initially formed
polymorph were determined in the temperature range from
30 uC to 60 uC (55 uC for nifedipine films from solution in
dichloromethane). In a typical experiment a heating rate of 5
uC per minute was applied. At each temperature a minimum of
eleven pictures were taken for the determination of the crystal
growth rate. Images were taken with intervals between 1 s to 10
s adjusted to the speed of the crystal front propagation. The
crystal growth rates were determined from the propagation of
the crystallization front. These moving fronts are sharply
defined. For each solvent at least seven samples were prepared
and their crystallization processes investigated over the whole
temperature range. From these repeated experiments mean
crystallization growth rates and their standard deviations can
be determined reproducibly.
Dielectric measurements
Dielectric measurements were carried out with an a-A analyzer
by Novocontrol, which allows for frequency resolved measure-
ments of the dynamic susceptibility in the range of n = 1022–
106 Hz. The sample cell is an axial symmetric parallel plate
capacitor with an electrode surface of A = 2.546 1024 m2. The
distance between the electrodes is d = 64 mm determining the
empty cell capacity of C0 = 35 pF and the sample volume V =
1.63 6 1028 m3. Thus the sample mass can be estimated to
15–20 mg. Ref. 22 gives a detailed description of the cell
design. During isothermal measurements the sample tem-
perature was kept constant within ¡0.2 K with the help of a
Quatro-H temperature controller by Novocontrol. Liquid
nitrogen was used as cryogenic.
Results and discussion
Thin nifedipine films were produced on a soda lime silicate
glass surface by evaporation of a droplet of nifedipine
solutions using six different solvents (see Fig. 2 and 5).
Raman spectroscopy revealed that the thin glassy nifedipine
film consisted in all cases of the amorphous form of
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nifedipine, also denoted as g-nifedipine.21 A few minutes after
the solvent evaporation, crystallization started statistically
distributed over the surface of the amorphous nifedipine
films. The crystallization propagated rapidly with spherulitic
morphology. These general observations are independent of
the specific solvent used for the production of the thin films.
The crystallization process was then monitored by light
microscopy. Fig. 3 displays microscopy images taken sequen-
tially during the crystallization process of a nifedipine film
produced from a solution of nifedipine in acetone. Within this
frame, the images show the propagation of a crystallization
front in the thin nifedipine film. The light microscope images
(see Fig. 3) display the transformation of the amorphous form
to the crystalline metastable b-modification of nifedipine. The
assignment of the phases and their purity was carried out and
verified unambiguously via Raman measurements (see e.g.
Fig. 4 and text below).8,23,24
The mean crystal growth rate was determined from the
propagation of the crystallization front. These moving fronts
are very pronounced, spatially extended, sharply defined, and
easy to follow. Therefore, reliable growth rate measurements
can be conducted between an arbitrarily indicated starting line
(dashed black line in Fig. 3) and the propagating front line
(dashed red line in Fig. 3). The specifically chosen crystal-
lization front in Fig. 3 propagates with 13.3 ¡ 0.3 mm s21.
Our observations presented here point to the fact that the
glassy form of nifedipine, when freshly prepared from
different solutions, undergoes extremely fast crystallization
in each case. This crystallization rate is not so high, when the
film is calorimetrically relaxed, aged, or has a specific thermal
history. Under these conditions the excess free energy value is
closer to the free energy of the thermodynamically most stable
polymorph and therefore more stable against crystallization.
These observations and arguments are well documented for
nifedipine and nifedipine alloys in the literature.17,18
The crystal growth from the amorphous films was also
monitored with Raman microspectroscopy to identify the
crystallizing polymorphs of nifedipine. Fig. 4 shows the
Raman spectra for the crystallization of thin films produced
from a solution in acetone (Fig. 4, left) and a solution in
dichloromethane (Fig. 4, right). The crystallization process is
followed starting with the amorphous film (bottom), which
exhibits the Raman signals of amorphous g-nifedipine. For
both solvents, the in situ Raman spectra show rapid crystal-
lization to intermediate phases. In case of acetone the
metastable b-modification was formed from the amorphous
precursor after 16 s. For dichloromethane the Raman spectra
show features that could not be assigned to the known
modifications of nifedipine as described by Chan et al.21 For
both solvents the crystallization of the intermediate phase is
followed by a transformation to the thermodynamically stable
a-modification (top).
The assignment of the different modifications is unambig-
uous by the characteristic C–C–O–vibration of the ester groups
at 1215 cm21 (g, b) and 1225 cm21 (a), the symmetric
stretching vibration of the NO2-group at 1355 cm
21 (g) and
1348 cm21 (a, b) as well as the CLC stretching vibration at 1652
cm21 (b), respectively, 1648 cm21 (g, a). Furthermore, the ester
bond stretching modes in the wave number region between
1660 and 1710 cm21 can be used for differentiation. The CLO
stretching vibration at 1680 cm21 with high relative intensity
is characteristic for the a-modification while the spectra of the
b-form display signals at 1663 cm21, 1675 cm21 and 1701
cm21.21 The amorphous g-nifedipine is characterized by
broader peaks compared to the crystalline material.
The Raman spectra of the intermediate phase observed for
the crystallization of the thin films from dichloromethane (see
Fig. 4, right) show only slight differences when compared to
the spectra of the known nifedipine polymorphs. Regarding
the characteristic signals of the different nifedipine poly-
morphs, the new polymorph was distinguished from the other
modifications by signals at 1214 cm21, 1364 cm21, 1638 cm21,
1655 cm21 and 1703 cm21. Therefore we presume that this
might be a new polymorph of nifedipine. Structural analysis of
this compound is in progress.
The mean crystal growth rates of the first crystallizing
phase were determined from at least seven repeated experi-
ments as a function of temperature depending on the different
solvents. Fig. 5 displays the mean crystal growth rates with
their respective standard deviation for the transformation of
the amorphous material to the initially crystallizing poly-
morphic modification. For all solvents the resulting amor-
Fig. 3 Light microscope images of the crystal growth (dashed black line) of
crystalline nifedipine at room temperature in a thin amorphous nifedipine film
produced via evaporation of a solution in acetone (A–F, total width and height
of a single image: 610 mm6 258 mm). The images are taken with an interval of
2 s.
Fig. 2 Sketch of the sample preparation.
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phous nifedipine film crystallized unusually fast. The crystal
growth rates are in the order of 10 mm s21.
Acetone
The crystal growth rates for the thin amorphous nifedipine
films obtained from a solution in acetone were in the range of
9 mm s21 to 13 mm s21. This is in accordance with previously
published data.8 The crystal growth rates increase when the
temperature increases from 30 uC to 45 uC. The rates stagnate
or even decrease when the temperature is between 50 uC to 60
uC. The thin film from acetone revealed only the Raman
signals of the amorphous g-nifedipine. Signals of the solvent
could not be detected (see Fig. S1, ESI3). The amorphous film
crystallized to the b-modification which transformed to the
stable a-nifedipine, as displayed in Fig. 4.
Ethyl acetate
The crystallization of a thin film from a solution in ethyl
acetate proceeds with 6.5 mm s21 at 30 uC, and then decreases
to 5.5 mm s21 at 35 uC. Subsequently, the growth rate increases
with temperature to 13.5 mm s21 at 55 uC. The Raman spectra
of the thin films can be assigned to the amorphous form of
nifedipine, without contributions of the solvent (see Fig. S1,
ESI3). The initial crystal nuclei form very fast yielding
transparent, almost colourless spherulites which soon stop
growing. The crystallization then restarts from these nuclei
with slower crystal growth rate. The Raman spectra of the
white nuclei revealed the features of a new polymorph of
nifedipine as a pure phase (see Fig. S2, ESI3). The crystallites
formed during the slower second crystallization process were
identified as a mixture of b-nifedipine and the new polymorph
(see Fig. S3, ESI3).
Fig. 4 Time-resolved Raman spectra of nifedipine samples measured during the growth of the crystallites from the thin films produced from a solution in acetone
(left), and in dichloromethane (right) starting with the amorphous film (bottom) to the thermodynamically stable crystalline material (top). The spectra show the rapid
evolution of intermediate phases in case for acetone b-nifedipine (24 s). For dichloromethane, a new nifedipine modification (47 s) and the subsequent conversion to
the a-nifedipine (at 73 s for acetone and 89 s to 110 s for dichloromethane). Note the transition to the stable a phase occurs at times longer than 73 s.
Fig. 5 Mean crystal growth rates (symbols) of nifedipine crystals from an
amorphous film produced from solutions in different solvents. The extension of
the bars reflects the results of several repeated experiments. The crystal growth
rates are shown as a function of temperature in steps of 5 uC.
This journal is  The Royal Society of Chemistry 2013 CrystEngComm, 2013, 15, 4062–4069 | 4065
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Acetonitrile
The crystal growth rates of amorphous films produced from a
solution of nifedipine in acetonitrile are in the range between
18 mm s21 to 25 mm s21. The standard deviation is very high
and a dependence of the crystal growth rate on the
temperature is not clearly detectable. For a given temperature
the variation in the crystal growth rates is large. Nevertheless
the mean crystal growth rate of the films from acetonitrile is
the highest amongst all investigated solvents. The Raman
spectra of the amorphous film produced from a solution of
nifedipine in acetonitrile show the features of the amorphous
form and also small contributions of the solvent at 2253 cm21
(see Fig. S1, ESI3). Time-resolved Raman spectra collected
during the crystallization process revealed a direct crystal-
lization of the amorphous form to the thermodynamically
stable a-modification (see Fig. S4, ESI3).
Chloroform
The crystallization of amorphous nifedipine films produced
from a solution in chloroform is rather slow as compared to
the crystallization from thin films produced from the other
solvents. The crystal growth rate rises from 1 mm s21 at 30 uC
to 2.7 mm s21 at 60 uC starting with a fast increase in velocity
up to 50 uC followed by slightly slower crystal growth rates. The
Raman spectra of the thin films can be assigned to the
amorphous g-nifedipine, but reveal also the three most intense
signals of chloroform at 263, 368 and 668 cm21 (see Fig. S1,
ESI3). The Raman spectra of the growing spherulites can be
assigned to the new polymorph of nifedipine whereas the
spectra directly at the centre of the spherulites show
contributions from g-nifedipine, the new polymorph of
nifedipine and a-nifedipine (see Fig. S5, ESI3).
Dichloromethane
For thin films from a solution in dichloromethane a slight
increase of the crystal growth rates with rising temperatures
was observed starting from 8 mm s21 at 30 uC to 9 mm s21 at 45
uC. At 50 uC and 55 uC the growth rate dropped to 7.6 mm s21.
The Raman spectra of the amorphous film exhibit the signals
of the amorphous film with a fraction of remaining solvent,
verified by the signals at 284 cm21 and 702 cm21 (see Fig. S1,
ESI3). In situ Raman spectroscopy revealed the transformation
of the amorphous film to the final thermodynamically stable
crystalline product a-nifedipine. Half of the conducted crystal-
lization experiments yielded directly the a-modification from
the amorphous precursor. In the other cases the formation of
an intermediate phase could be detected. The Raman spectra
showed the rapid crystallization of the new polymorph and
subsequent transformation to the stable a-nifedipine within
40 s to 60 s, see Fig. 4, right.
Tetrahydrofuran
Thin amorphous nifedipine films from a solution in tetra-
hydrofuran crystallize with growth rates between 2.4 mm s21 at
30 uC and a maximum of 3.5 mm s21 at 45 uC. With rising
temperatures the growth rates exhibit an increase up to 45 uC
followed by a slight decrease of the growth rates down to 3.2
mm s21 at 60 uC. The thin amorphous films contain small
amounts of solvent as proven by an additional signal at 914
cm21 in the Raman spectra of g-nifedipine (see Fig. S1, ESI3).
The crystallization was monitored by time-resolved Raman
spectroscopy. The amorphous film crystallizes in nearly
transparent/colourless spherulites. Again the Raman spectra
show the features of a new polymorph of nifedipine (see Fig.
S6, ESI3). The new form is at least stable for 30 min, but at the
center of the spherulites the Raman spectra reveal already the
transformation to the thermodynamically stable form a-nife-
dipine. All Raman spectra of the crystallites of the new
nifedipine form still show the most intense signal from
tetrahydrofuran at 914 cm21 also in the a-form at the nucleus.
The newly determined mean crystal growth rates derived for
the thin films from different solutions are displayed in Fig. 6
together with the growth rates reported in the literature for the
supercooled melt of bulk nifedipine. Zhu et al. investigated the
crystallization of nifedipine crystals in the bulk, on the surface
of a nifedipine layer and on a gold coated nifedipine surface.3
They observed high crystal growth rates on the surface of the
uncoated nifedipine material and interpreted this phenom-
enon as surface-enhanced diffusionless crystal growth. The
growth rates from the thin nifedipine films produced by
evaporation of a nifedipine solution in different solvents are
reproducibly three to four orders of magnitude higher. These
high growth rates can only be explained in terms of
diffusionless crystal growth.
Since dielectric spectroscopy is a convenient technique for
studying molecular dynamics in a very accurate way,25–27 we
applied the method to nifedipine. As a first step we
investigated the dielectric relaxation features of the super-
cooled liquid in order to determine the structural relaxation
times ta, which are expected to control the crystallization
process. Fig. 7a shows selected dielectric susceptibility spectra
Fig. 6 The crystal growth rates derived for the crystallization from thin
nifedipine films as a function of the temperature for the various solutions used
to prepare the amorphous films. The data are displayed in comparison to the
crystal growth rates from the supercooled melt. The black symbols show the
time constant of the primary relaxation ta(T) derived from dielectric measure-
ments. The grey data points with open symbols have been reproduced from the
literature.3 These data points reflect the crystallization of bulk crystals, crystals
grown on the surface of bulk nifedipine, and crystals grown on gold coated
surfaces of bulk nifedipine.
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(black lines) clearly displaying the main relaxation (a-)peak
shifting to lower temperatures upon cooling. In addition, a so-
called excess wing is found as an additional power law
contribution on the high frequency side of the main relaxation
peak as is typical for many molecular glass formers.28 Below Tg
a very weak secondary relaxation process is identified. As
shown in ref. 29 and 30 the excess wing contribution can be
included in a phenomenological interpolation of the spectra
(dashed line in Fig. 7a, also including a conductivity
contribution). The analysis yields the time constants ta(T) (cf.
Fig. 7b), which agree well with those reported in the
literature.13 By tracking the frequency positions of the b-peak
we determined its time constants via tb = (2pnmax)
21 and
included them in Fig. 7b. The tb follow an Arrhenius
temperature dependence with an activation energy Ea = 51 kJ
mol21. In contrast to that, the a-process exhibits a super-
Arrhenius temperature dependence, as is typically found for
supercooled liquids. The glass transition temperature is
determined to Tg = T(ta = 100 s) = 316 K. For comparison the
ta(T) are also included in Fig. 6 (black dots). The much
stronger temperature dependence of the ta compared to the
one of the crystal growth rates indicates the decoupling of the
crystallization kinetics from the mechanism of diffusion, as
already discussed.
The transition from the highly viscous liquid to a crystalline
phase, the latter displaying a very weak dielectric loss, can be
monitored in a time resolved way by re-measuring the
dielectric spectra in constant time intervals. In Fig. 8a we
show the phase transition at 321 K (close to Tg) with a time
increment of about 16 h, i.e. the total transformation covered
roughly 106 s. In Fig. 8b we present the time dependence of the
amplitude of the susceptibility at constant t = 0.1 Hz. Clearly,
non-exponential transformation kinetics is observed.
Displaying the data on linear time scale (inset) one recognizes
a bimodal decay which can be approximated by two Avrami
decays with respective exponents n (cf. inset Fig. 8b). The slow
Fig. 7 (a) Dielectric susceptibility spectra of nifedipine above (symbols) and
below Tg (solid lines) at indicated temperatures (5 K steps in the range of 225–
280 K. A small loss of signal amplitude due to partial sample crystallization
above Tg was compensated here by scaling the high-T data to the amplitude of
the 318 K curve). Dashed lines: interpolations by a phenomenological model as
described in the text. (b) Corresponding relaxation times ta (crosses) calculated
from the fit parameters and tb (squares, inverse peak frequencies). Solid line:
Arrhenius interpolation (activation energy indicated). Dashed line: interpolation
by a Vogel–Fulcher–Tammann equation.
Fig. 8 (a) Dielectric spectra of nifedipine at indicated temperatures (data from
Fig. 7a, connected symbols). Dashed lines: spectra at 321 K at different
measurement times (cf. text above). (b) Spectral amplitude at constant
frequency (v = 0.1 Hz) and temperature (T = 321 K) plotted versus logarithmic
measurement time (squares). Solid lines: piece-wise interpolations with two
Avrami laws (exponents indicated). Inset: the same data with linear time
abscissa.
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initial decay described with n = 0.8 bends over into a much
faster decay with n = 2.7 after about 5 6 105 s. However, it is
not easy to unambiguously attribute the two decays to
diffusion controlled or diffusionless crystal growth, respec-
tively. Analyzing the produced crystalline sample after full
transformation by XRD we identified the a-modification of
nifedipine. Still it may be possible that the initial slow decay
reflects the transformation of the highly supercooled liquid to
a metastable modification. Attempting to monitor the bimodal
kinetics at higher temperatures we only observed a mono-
modal transformation. We note that we were able to observe
crystallization even below Tg. However, due to the fact that at
such temperatures the main relaxation process is situated
beyond the accessible frequency range and the emerging
crystalline phase shows a very weak dielectric signal, we
cannot monitor the transformation process quantitatively.
Nevertheless, this may indicate the occurrence of a fast
(diffusionless) mode of crystallization. The experimental
identification of the phase formed during the first stage
appears not to be directly possible. Only a combination with
other experimental techniques may answer these open
questions.
The different solvents used for the formation of amorphous
films have a specific influence on the formation of the
crystalline phase. We observed that the initially formed
crystalline phase can be a-nifedipine (acetonitrile, dichlor-
omethane), b-nifedipine (acetone) or a novel polymorphic
phase of nifedipine (ethyl acetate, chloroform, dichloro-
methane, tetrahydrofuran). This shows that the solvent directs
selectively the first formed crystalline polymorph. It is there-
fore reasonable to assume that the solvent–solute interactions
lead to a specific self-assembly of the nifedipine molecules in
the amorphous film. This kind of preordering might also be
the reason for the unusually high crystallization rates.
Nifedipine self-association is a prerequisite for the very fast
i.e. diffusionless crystallization. In some cases, traces of the
solvents remain in the amorphous films. The presence of these
traces does not show any distinct influence on the crystal
growth rates. Hence the self-association and preordering of the
nifedipine molecules in the amorphous films seems to be very
strong. In addition to these observations, it is remarkable that
different solvents have the capability to trigger the form of the
initially crystallizing polymorph. For all investigated solvents,
the crystal growth rates for the transformation from the
amorphous films to the first crystalline phase increase with
temperature up to 45 uC. A further increase of the temperature
does not result in higher growth rates but stagnation or even a
slight decrease of the growth rates is observed. Displayed
standard deviations for the growth rates are quite large,
especially for higher temperatures. This general phenomenon
might be an indication for the competing crystallization of
another polymorph starting at higher temperatures.
Conclusions
We conclude that nifedipine crystallizes with a strong
diffusionless propensity. Observing three different solid forms
(glassy g-form, b-form, a-form) of nifedipine within less than
ten minutes is remarkable. Different solvents yield amorphous
nifedipine films with different crystal growth rates, but the
crystallization process as such is always fast. Crystallisation
experiments at elevated temperatures (around 45 uC up to 60
uC) do not lead to higher crystallization rates. Instead a
stagnation or even decrease of the crystallization rate is
observed. This unexpected behaviour is tentatively interpreted
in terms of a competing crystallization process of a novel
polymorph.
The growth rates are four orders of magnitude higher as
compared to crystal growth rates driven solely by diffusion. A
crystallization mechanism based on the self-association and
preordering of the molecules in the freshly formed amorphous
state is suggested. These findings and observations may also
be applicable to other organic compounds with a Tg around
room temperature.
The phenomenon of rapid crystallization from amorphous
films is of importance with respect to pharmaceutical
applications. Poorly soluble active pharmaceutical ingredients
are sometimes formulated and marketed in their amorphous
form. Hence, the stability of the amorphous form against
crystallization and the possibility of competitive fast crystal-
lization in solution, and on films on surfaces need to be
characterized in a broader temperature range in order to
unravel the basic underlying fast crystallization mechanisms.
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